Hoyer D, Bell G I, Berelowitz M, Epelbaum J, Feniuk W, Humphrey P P, O'Carroll A M, Patel Y C, Schonbrunn A, Taylor J E
Sandoz Pharma Ltd., Basel, Switzerland.
Trends Pharmacol Sci. 1995 Mar;16(3):86-8. doi: 10.1016/s0165-6147(00)88988-9.
There is considerable controversy about the classification and nomenclature of somatostatin receptors. To date, five distinct receptor genes have been cloned and named chronologically according to their respective publication dates, but two were unfortunately given the same appellation (SSTR4). Consensually, a nomenclature for the recombinant receptors has been agreed according to IUPHAR guidelines (sst1, sst2, sst3, sst4, and sst5). However, a more informative classification is to be preferred for the future, employing all classification criteria in an integrated scheme. It is already apparent that the five recombinant receptors fall into two classes or groups, on the basis of not only structure but also pharmacological characteristics. One class (already referred to by some as SRIF1) appears to comprise sst2, sst3 and sst5 receptor subtypes. The other class (SRIF2) appears to comprise the other two recombinant receptor subtypes (sst1 and sst4). This promising approach is discussed but it is acknowledged that much more data from endogenous receptors in whole tissues are needed before further recommendations on somatostatin receptor nomenclature can be made.
关于生长抑素受体的分类和命名存在相当大的争议。迄今为止，已克隆出五个不同的受体基因，并根据它们各自的发表日期按时间顺序命名，但不幸的是，其中两个被赋予了相同的名称（SSTR4）。根据国际药理学联合会（IUPHAR）的指导方针，已就重组受体的命名达成共识（sst1、sst2、sst3、sst4和sst5）。然而，未来最好采用一种更具信息性的分类方法，将所有分类标准纳入一个综合方案。已经很明显，这五个重组受体不仅基于结构，而且基于药理学特性可分为两类或两组。一类（一些人已经将其称为SRIF1）似乎包括sst2、sst3和sst5受体亚型。另一类（SRIF2）似乎包括另外两个重组受体亚型（sst1和sst4）。本文讨论了这种有前景的方法，但也承认，在能够就生长抑素受体命名提出进一步建议之前，还需要来自全组织内源性受体的更多数据。
